Coya Therapeutics Files 2025 Proxy Statement

Ticker: COYA · Form: DEF 14A · Filed: May 16, 2025 · CIK: 1835022

Coya Therapeutics, Inc. DEF 14A Filing Summary
FieldDetail
CompanyCoya Therapeutics, Inc. (COYA)
Form TypeDEF 14A
Filed DateMay 16, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

Related Tickers: COYA

TL;DR

Coya Therapeutics (COYA) filed its proxy statement for the June 26 meeting. Board members Fred Grossman, David Snyder, Howard Berman listed.

AI Summary

Coya Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on May 16, 2025, for its annual meeting scheduled for June 26, 2025. The filing covers the fiscal year ending December 31, 2024. Key individuals mentioned in relation to board memberships include Fred Grossman, David Snyder, and Howard Berman, all designated as Members, with their appointments noted on June 3, 2024.

Why It Matters

This filing provides shareholders with essential information regarding the company's governance, director nominations, and other matters to be voted on at the upcoming annual meeting, influencing shareholder decisions and company direction.

Risk Assessment

Risk Level: low — This is a routine proxy filing providing information for an upcoming shareholder meeting and does not contain new financial or operational disclosures that would immediately impact risk.

Key Numbers

  • 20250626 — Annual Meeting Date (Shareholders will vote on company matters on this date.)
  • 2024-12-31 — Fiscal Year End (The proxy statement covers the company's performance up to this date.)

Key Players & Entities

  • Coya Therapeutics, Inc. (company) — Registrant
  • Fred Grossman (person) — Board Member
  • David Snyder (person) — Board Member
  • Howard Berman (person) — Board Member

FAQ

What is the purpose of this DEF 14A filing?

The purpose of this DEF 14A filing is to provide shareholders with information for the upcoming annual meeting on June 26, 2025, including details about director nominations and other voting matters.

Who are the key individuals mentioned in relation to the board?

Fred Grossman, David Snyder, and Howard Berman are mentioned as Members of the board, with their appointments noted on June 3, 2024.

When is Coya Therapeutics' annual shareholder meeting scheduled?

The annual shareholder meeting is scheduled for June 26, 2025.

What fiscal year does this proxy statement cover?

This proxy statement covers the fiscal year ending December 31, 2024.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on May 16, 2025.

Filing Details

This Form DEF 14A (Form DEF 14A) was filed with the SEC on May 16, 2025 by Fred Grossman regarding Coya Therapeutics, Inc. (COYA).

View full filing on EDGAR

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.